Everolimus has recently received approval for immunosuppressive therapy in heart transplant recipients in Austria and Germany. At our heart center we have treated 114 patients with everolimus since January 2004. Here we describe 6 cases of lingual angioedema (corresponding to 5.3% of the patients). Symptoms occurred within 2 to 41 days after initiation of therapy. In 5 out of the 6 patients, lingual angioedema disappeared with anti-allergic treatment alone. However, in one patient, two severe recurrent episodes of lingual angioedema occurred so that therapy had to be discontinued. We conclude that the potentially life-threatening condition of lingual angioedema should be considered a severe drug reaction after initiation of everolimus therapy in heart transplant recipients.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00007890-200504270-00020DOI Listing

Publication Analysis

Top Keywords

lingual angioedema
20
immunosuppressive therapy
8
therapy heart
8
heart transplant
8
transplant recipients
8
lingual
5
angioedema
5
everolimus
4
therapy everolimus
4
everolimus associated
4

Similar Publications

Management of difficult airways in the emergency department is challenging. Herein, we report a case of successful management of severe upper airway obstruction caused by angioedema, where intubation was achieved using a dual-function video laryngoscope and bronchoscope system in the emergency department for a patient with severe upper airway stenosis due to angioedema. A 74-year-old obese man with dyspnea presented to our emergency department.

View Article and Find Full Text PDF

Hereditary angioedema in children: Review and practical perspective for clinical management.

Pediatr Allergy Immunol

December 2024

French National Reference Center for Angioedema (CREAK), Center of Excellence and Reference (ACARE), Internal Medicine Department, Grenoble Alpes University Hospital, Grenoble, France.

Background: Hereditary angioedema (HAE) in children has specific features and requires multidisciplinary management.

Methods: We performed a literature search and underwent in-depth discussions to provide practical tools for physicians.

Results: HAE is a rare, life-threatening genetic disorder.

View Article and Find Full Text PDF
Article Synopsis
  • - Systemic lupus erythematosus (SLE) can manifest in various ways, making it hard to diagnose; this case involved a 23-year-old woman who presented with severe swelling and respiratory issues, which were later identified as symptoms of SLE.
  • - Initial treatment involved high-dose steroids and pulse therapy with methylprednisolone; however, the patient developed sepsis and an SLE flare due to an infection at the tracheostomy site.
  • - After broad-spectrum antibiotics and a gradual reduction of steroids, along with maintenance therapy with azathioprine, the patient's condition improved, leading to the successful reversal of the tracheostomy and her discharge from the hospital.
View Article and Find Full Text PDF

Objective: To describe a case of a suspected anaphylactoid reaction to mannitol in a dog.

Case Summary: A 1-year-old, neutered female French Bulldog was anesthetized for a T12-T13 dorsal laminectomy surgery for a previously diagnosed spinal arachnoid diverticulum. Perioperatively, the spinal cord appeared grossly edematous, and IV mannitol administration was elected.

View Article and Find Full Text PDF

Objective: To report a case of drug-induced isolated angioedema secondary to the use of Entresto (Valsartan/Sacubitril).

Case Summary: A 75-year-old White man presented with swelling of the uvula with a normal tongue shape and gradual onset of speech difficulty, shortness of breath, and difficulty swallowing after taking his chronic medication Entresto (sacubitril/valsartan). The main possibility considered was uvular angioedema, other potential causes were not identified.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!